Prognosis of Elderly Patients With Acute Myelogenous Leukemia: Analysis of 126 AML Cases
- 61 Downloads
We retrospectively analyzed 126 acute myelogenous leukemia (AML) patients aged ≥60 years who had all been referred to the same hematological department between 1989 and 1999. In 76 de novo AML cases, 53 patients (median age, 72 years) were treated with combination chemotherapy (CT) for remission induction. Complete remission (CR) rate was 57.1%. The median overall survival (OS) was 16 months, and the rate of 3-year OS was 28%. The favorable prognostic factors were performance status ≥2, cholinesterase ≥100 IU, and intermediate or favorable karyotype (P < .01). Seventeen patients (median age, 78 years) with hypocellular bone marrow or poor general condition were treated with low-dose cytosine arabinoside (LDAraC). In these patients, the CR rate was 50% and the median OS was 11 months, with an OS estimate at 3 years of 14%. All patients with hypocellular bone marrow who received LDAraC for 21 days achieved CR. In 50 patients who developed AML following a myelodysplastic syndrome (MDS/AML), 22 patients (median age, 74 years) were treated with CT, and 14 (median age, 74 years) patients were treated with LDAraC. The CR rates were 22.7% and 21.4%, respectively, and the median OS durations were 8 months and 11 months, respectively. There were no significant factors that would indicate a good prognosis in MDS/AML patients.
Key wordsElderly AML Prognostic factor Combination chemotherapy Low-dose AraC
Unable to display preview. Download preview PDF.
- 1.Brinker M. Estimate of overall treatment results in acute nonlym- phocytic leukemia based on age specific rates of incidence and of complete remission.Cancer Treat Rep. 1985;69:5–11.Google Scholar
- 6.Lowenberg B, Suciu S, Archimbaud E, et al. Use of recombinant granulocyte-macrophage colony-stimulating factor during and after remission induction chemotherapy in patients aged 61 years and older with acute myeloid leukemia (AML): final report of AML-11, a phase III randomized study of the leukemia cooperative group of European Organization for the Research and Treatment of Cancer (EORTOC-LC6) and the Dutch Belgian Hemato- Oncology Cooperative Group (HOVON).J Clin Oncol. 1997;90:2952–2961.Google Scholar
- 8.Mitelman F, ed.An International System for Human Cytogenetics Nomenclature. Basel: Karger; 1995.Google Scholar
- 13.Lowenberg B, Suciu S, Archimbaud E, et al. Mitoxantrone versus daunorubicin in induction-consolidation chemotherapy—the value of low dose cytarabine for maintenance of remission, and an assessment of prognostic factors in acute myeloid leukemia in elderly: final report of the Leukemia Cooperative Group of the European Organization for the research and treatment of cancer and the Dutch-Belgian Hemato-Oncology Cooperative HOVON Group randomized phase III study AML9.J Clin Oncol. 1998;16:872–881.CrossRefPubMedGoogle Scholar
- 15.Buchner T, Hiddemann W, Loffer H, et al. Treatment of AML in the elderly full-dose versus reduced induction treatment [abstract].Blood. 1995;86(suppl 434a). Abstract 1721.Google Scholar
- 17.Leith CP, Kopecky KJ, Godwin J, et al. Acute myeloid leukemia in elderly: assessment of multidrug resistance (MDR1) and cytoge- netics distinguishes biologic subgroups with remarkably distinct response to standard chemotherapy. A Southwest Oncology Group study.Blood. 1997;89:3323–3329.PubMedGoogle Scholar